Vittoriabio

3 known investors

Vittoria Biotherapeutics is a clinical-stage company developing next-generation autologous CAR T-cell immunotherapies for oncology and immunology, built on its Senza5 platform that uses CD5 signaling modulation and a 5-day manufacturing process. Its lead candidate, VIPER-101, is in a Phase 1 trial for T-cell lymphoma.